PubMed Health⌕ Search

Biomedical subjects

P R Goodyer

Publications and source records attributed to P R Goodyer.

At least 37 records · Page 2Linked to original sources

Congenital deficiency of a 20-kDa subunit of mitochondrial complex I in fibroblasts.

The first component of the mitochondrial electron-transport chain is especially complex, consisting of 19 nuclear and seven mitochondrion-encoded subunits. Accordingly, a wide range of clinical manifestations are produced by the various mutations occurring in human populations. In this study, we analyze the subunit structure of complex I in fibroblasts from two patients who have distinct clinical phenotypes associated with complex I deficiency. The first patient died in the second week of life from overwhelming lactic acidosis. Severe complex I deficiency was evident in her fibroblasts, since alanine oxidation was markedly reduced whereas succinate oxidation was normal. Absence of a 20-kDa subunit was demonstrable when newly synthesized proteins were immunoprecipitated from pulse-labeled fibroblasts by anti-complex I antibody. Disordered assembly or decreased stability of the complex was suggested by deficiency of multiple subunits on Western immunoblots. The second patient exhibited a milder clinical phenotype, characterized by moderate lactic acidosis and developmental delay in childhood and by onset of seizures at 8 years of age. Oxidation studies demonstrated expression of the complex I deficiency in fibroblasts, but no subunit abnormalities were detected by immunoprecipitation or Western immunoblotting. This report demonstrates the utility of cultured fibroblasts in studying mutations affecting synthesis and assembly of complex I.

Alanine↗

Excretion of epidermal growth factor-like material in acute Henoch-Schönlein purpura nephritis.

In Henoch-Schönlein purpura nephritis (HSPN), glomeruli may develop cellular "crescents" composed of infiltrating monocytes and proliferating renal epithelia. In this study, we demonstrate that peripheral human monocytes can release an epidermal growth factor (EGF)-like substance detectable by a radioreceptor assay, which recognizes both EGF and transforming growth factor-alpha (TGF-alpha), but not with a radioimmunoassay, which recognizes only EGF. Furthermore, we report that urine from pediatric patients during the acute phase of HSPN contains a similar EGF-like species in addition to the endogenous EGF which is normally present. The EGF-like material was not present in urine from nine healthy children or from six children with acute post-streptococcal glomerulonephritis. The extent of crescent formation in our patients is uncertain, since renal biopsy was performed in only one case. However, we speculate that the urinary material resembling TGF-alpha which appears during the acute phase of HSPN may derive from monocytes infiltrating the kidney.

Acute Disease↗

Renal synthesis of epidermal growth factor is unchanged by vitamin D deficiency.

In mammalian kidney, epidermal growth factor (EGF) is produced as a small internal domain of an abundant high molecular weight peptide associated with the luminal membrane of the thick ascending limb of Henle's loop and distal convoluted tubule. At present, there is no evidence to indicate a mitogenic function for the EGF-containing molecule in kidney; consideration of its molecular structure suggests the possibility of a membrane-associated physiologic role. In this study, we examine regulation of renal EGF synthesis during induction of vitamin D deficiency in mice. Despite evidence of marked hyperparathyroidism, urinary excretion of EGF was equivalent in control (2.54 +/- 0.72 micrograms/mg creatinine) and vitamin D deficient (2.13 +/- 0.97 micrograms/mg creatinine) animals. Similarly, EGF mRNA levels in kidney were comparable in the two groups. These data indicate that parathyroid hormone has no effect on renal EGF regulation, although it is known to stimulate calcium reabsorption in distal nephron segments.

Animals↗

Renal tubular cells are potential targets for epidermal growth factor.

Epidermal growth factor (EGF) is a potent polypeptide mitogen with various receptor-mediated growth effects on cells from the skin, breast, and gastrointestinal tract. Recent studies indicate that EGF is produced in the kidney and is excreted in the urine, but the biological significance of renal EGF is uncertain. We demonstrate in vitro mitogenicity of EGF for LLC-PK1 cells, a tubular epithelial cell line derived from pig kidney cortex. Furthermore, when subconfluent monolayers of LLC-PK1 cells are exposed to EGF for 24 h, sodium-dependent phosphate transport is stimulated (209-410% of control). These cells possess EGF-specific high-affinity binding sites at their surface (Kd 300-700 pM) but cannot synthesize the growth factor. EGF binding sites are not a peculiarity of the LLC-PK1 cell line, since similar sites are present on MDCK cells (derived from dog kidney distal tubule or collecting duct), primary cultures of mouse proximal tubular cells, and freshly prepared membrane fractions from mouse kidney. Cortical basolateral membranes are highly enriched in EGF binding sites, whereas EGF binding by brush-border membrane fractions is minimal and is compatible with contamination.

Animals↗

Amelioration of murine lupus nephritis by dimethylsulfoxide.

Dimethylsulfoxide was given to NZB/W F1 female mice from age 10 weeks to see if proteinuria and glomerular injury could be reduced. Twenty mice were randomly assigned to saline or DMSO treatment groups and the following studies were done: urine protein determination, serum concentrations of creatinine, IgG, C3, and albumin; and ANA titers. Kidney tissue were studied by light, immunofluorescent and electron microscopy. DMSO-treated mice had significant reductions in protein excretion at 5 and 6.5 months of age; in urine protein/creatinine ratio at 6.5, 7, and; 7.5 months; in serum C3 at 7.5 months; and in serum creatinine concentration. There were no significant differences among serum IgG, nor among the ANA titers. Histopathologic studies revealed nearly normal kidneys in 5/6 DMSO-treated mice whereas 4/8 controls had severe mixed membranous and membranoproliferative glomerulonephritis. Ultrastructural studies revealed mesangial, subendothelial, and subepithelial deposits and membranous transformation of the glomerular capillary wall. DMSO therefore appears capable of ameliorating glomerular injury in NZB/W F1 mice.

Animals↗

Nephrocalcinosis and its relationship to treatment of hereditary rickets.

Renal ultrasonography was performed on 23 patients with X-linked hypophosphatemic rickets (XLH) and 11 patients with autosomal recessive vitamin D-dependent rickets (ARVDD). A pattern of increased echogenicity of the renal pyramids (ERP) was identified in 11/23 patients with XLH and 3/11 patients with ARVDD; this ultrasonographic finding has previously been associated with medullary nephrocalcinosis. Patients with XLH and ERP had significantly higher mean serum calcium and phosphate concentrations, more frequent episodes of hypercalcemia, and higher doses of oral vitamin D and phosphate during the first 3 years of therapy. Episodes of hypercalcemia were more frequent when patients received higher doses of vitamin D2 (greater than 4000 IU/kg/day) or 1,25-dihydroxycholecalciferol (greater than 40 ng/kg/day). Episodes of hypercalciuria were significantly increased at doses of greater than 20 ng/kg/day 1,25-dihydroxycholecalciferol. In patients with ARVDD, ERP was also correlated with vitamin D dose and frequency of hypercalcemia episodes. ERP was not associated with an elevation of serum creatinine or loss of urinary concentrating ability in either patient group.

Adolescent↗

Colchicine reduces proteinuria in passive Heymann nephritis.

Colchicine was given to rats in the heterologous phase of passive Heymann nephritis to see whether this drug could reduce proteinuria. Treatment with 0.06 mg/day for 14 days caused significant reductions in proteinuria and albuminuria. Administration of dimethyl sulfoxide (DMSO) alone or in combination with colchicine also reduced protein and albumin excretion. In a long-term experiment, rats treated with colchicine had significantly less proteinuria. After stopping therapy, urine protein excretion was similar to controls. No differences in glomerular C3 and IgG deposition were found between treated and control rats 24 h, 3,7 and 14 days after immunization. Depressed serum C3 levels were measured at 24 h in colchicine-treated rats. No difference in serum-circulating immune complexes was detected between the two groups. Concurrent administration of indomethacin and colchicine to rats with passive Heymann nephritis (PHN) partially reversed the reduction in proteinuria and albuminuria seen in rats treated with colchicine alone. The G.F.R, however, was significantly reduced in colchicine-treated rats as well as in rats treated with colchicine and indomethacin. Serum cholesterol and triglyceride levels were significantly lower in colchicine-treated rats than in controls. Serum cholesterol concentrations in rats given both colchicine and indomethacin were similar to control values. These findings suggest that colchicine reduces urine protein and albumin excretion, and hyperlipidemia in PHN. The finding that indomethacin partially blocks the effects of colchicine suggests that renal prostaglandin stimulation by colchicine may have been involved in the reduction in proteinuria.

Animals↗

Analysis of the Heymann nephritogenic glycoprotein in rat, mouse, and human kidney.

Passive Heymann nephritis is induced in rats by intravenous administration of antiserum raised against antigens of the renal proximal tubule. Evidence by Kerjaschki and Farquhar indicates that the critical nephritogenic is a high molecular weight glycoprotein (HMWgp) of rat renal brush border membrane. Their immunocytochemical studies also localize the nephritogenic antigen to the glomerular epithelial cell surface and may explain in situ formation of immune complexes at this locus in Heymann nephritis. We have confirmed the observations of Kerjaschki and Farquhar by demonstrating the HMWgp in extracts of rat brush border membrane and isolated glomeruli on sodium dodecyl sulfate-polyacrylamide (SDS-PA) (5%) gels. An antiserum raised to purified rat HMWgp identifies the antigen from rat or mouse kidney on Western blots. However, unlike rodent kidney, we were unable to detect a comparable HMWgp in extracts of human kidney on SDS-PA gels and found no cross-reactive material on Western blots of human brush border membrane proteins. Our observations suggest that human kidney lacks the nephritogenic antigen critical to initiation of Heymann nephritis in rodents.

Animals↗

Interactions of dimethyl sulfoxide and nonsteroidal anti-inflammatory agents in passive Heymann's nephritis.

The effect of treatment with indomethacin on the ability of dimethyl sulfoxide (DMSO) to reduce proteinuria in rats with passive Heymann's nephritis (PHN) was studied. PHN rats treated with DMSO alone excreted significantly less protein by day 14 than PHN rats treated with buffer or with indomethacin alone. Rats treated with DMSO excreted 19 +/- 6.0 mg protein/24 hr, and those treated with DMSO and indomethacin excreted 161 +/- 27.4 mg protein/24 hr (P less than 0.001). Rats treated with DMSO alone had significantly higher serum albumin and significantly lower serum cholesterol and triglyceride concentrations than those given the two drugs together. Glomerular deposits of C3 were reduced in DMSO-treated rats, but serum C3 concentrations and rat antirabbit serum antibody titers were similar in the two groups. When a higher dose of indomethacin (5 mg/kg) plus DMSO was used, protein excretion was significantly reduced. Rats treated with DMSO and acetylsalicylic acid (ASA) (37 mg/kg/day) or DMSO and meclofenamate (5 mg/kg/day) did not have a significant reduction in protein excretion compared with untreated controls. High-dosage indomethacin alone did not reduce proteinuria. Low doses of nonsteroidal anti-inflammatory agents therefore appear to block the effect of DMSO on proteinuria. This was in marked contrast to the finding of reduction of proteinuria induced by larger doses of indomethacin (5 mg/kg) plus DMSO. DMSO did not reduce proteinuria in rats with nephrosis induced by puromycin of aminonucleoside.

Animals↗

A gamma-aminobutyric acid-specific transport mechanism in mammalian kidney.

We describe high-affinity, sodium-dependent transport of gamma-aminobutyric acid in slices exposing basal lateral membranes and brush-border membrane vesicles prepared from rat renal cortex. In the presence of aminooxyacetic acid, to block gamma-aminobutyric acid oxidation, uptake into the intracellular space of slices was saturable (apparent Kt, 26 +/- 4 microM, mean and S.E.) and concentrative (steady-state distribution ratio at 50 microM gamma-aminobutyric acid, 47.7 +/- 2.4, mean and S.E.). Brush-border membrane vesicles accumulated gamma-aminobutyric acid in the presence of an inward-directed sodium chloride gradient, (apparent Kt, 30-36 microM) with the peak of 'overshoot' at 10 min. Uptake by vesicles responded to manipulation of the transmembrane potential gradient with valinomycin or impermeant anion. beta-Alanine inhibited gamma-aminobutyric acid transport by slices and brush-border membrane vesicles; inhibitors of neuronal-type gamma-aminobutyric acid transport (e.g., nipecotic and diaminobutyric acids) did not. An 'ABC test' indicated that gamma-aminobutyric acid and beta-alanine do not share a single carrier in either the brush-border or basal-lateral membrane of renal cortex. Influx of gamma-aminobutyric acid into brush-border membrane vesicles, at transequilibrium NaCl, was stimulated by trans-gamma-aminobutyric acid but not by trans-taurine. Ion gradient-driven gamma-aminobutyric acid co-transport was unaffected in freeze-thawed brush-border membrane vesicles; this treatment abolished beta-alanine and taurine co-transport. We conclude that rat kidney membranes (brush-border and basal-lateral) possess a gamma-aminobutyric acid-preferring, high-affinity transport mechanism.

Animals↗

Reduction of protein excretion by dimethyl sulfoxide in rats with passive Heymann nephritis.

Passive Heymann nephritis, a model of immune complex nephritis, was produced in rats by injection of rabbit antibrush border membrane vesicle antibodies to examine the effect of treatment of epimembranous glomerulonephritis with dimethyl sulfoxide. Administration of DMSO twice a day, 5 days a week for 4 weeks significantly reduced protein excretion in the autologous phase of the model. This beneficial effect occurred in animals in which treatment was started a day after administration of the antibody and persisted for 4 weeks after treatment was discontinued. Serum triglyceride concentrations were significantly decreased, whereas, BUN, serum cholesterol, and globulin levels were significantly, but not reproducibly, reduced. That DMSO did not reduce proteinuria to normal values in rats treated after proteinuria was well established, but was able to reduce proteinuria significantly. Treatment of normal rats and those with nephrotoxic serum nephritis did not reduce protein excretion. Glomeruli of rats with passive Heymann nephritis treated with DMSO studied by immunofluorescent microscopy appeared to have less fluorescence for IgG than control rats, but these differences were not significant. However, C3 deposits were significantly decreased in treated rats, but only during the first week of the disease and in vitro C3 fixation was also significantly reduced in glomeruli of rats that had been treated with DMSO. There was very little effect on serum complement activity: CH50 was reduced only on day 1 of treatment, whereas the alternate pathway activity and serum C3 concentration were unaffected. DMSO may therefore reduce protein excretion, in part, by inhibiting C3-dependent proteinuria. These studies indicate that DMSO is capable of significantly reducing protein excretion in rats with passive Heymann nephritis and that its action may involve reduction of complement deposition within the glomeruli during the heterologous phase. Toxic effects included a 2.5% mortality and decreased weight gain while being treated with larger doses of DMSO. Treatment with a much smaller dose succeeded in reducing proteinuria significantly without affecting weight gain. There was no evidence of drug-induced liver or renal damage.

Animals↗

Inherited lactic acidosis: correction of the defect in cultured fibroblasts.

We report a case of familial lactic acidosis, lethal in the newborn period. Studies in intact fibroblasts identified a defect in the oxidative pathway of pyruvate metabolism. Although assay of pyruvate dehydrogenase on cell sonicates was not appreciably reduced, flux through the enzyme and other mitochondrial multienzyme dehydrogenases was severely impaired in intact cells. Deficient lactate conversion to carbon dioxide could be repaired by the addition to the incubation medium of electron acceptors such as methylene blue (25 micrograms/ml) or dichlorophenolindophenol (25 micrograms/ml).

Acidosis↗

A perimortem protocol for suspected genetic disease.

A considerable portion of pediatric deaths represent disease with risk of recurrence in subsequent family members. Procedures to obtain samples of body fluids and tissues suitable for diagnosis of mendelian and chromosomal disorders are described. These procedures, the "perimortem protocol," are used in studying children who died of suspected but undiagnosed genetic disease.

Chromosome Aberrations↗

Properties of gamma-aminobutyric acid synthesis by rat renal cortex.

Substantial synthesis of gamma-aminobutyric acid occurs in rat renal cortex. Renal glutamate decarboxylase activity (24.3 +/- 2.9 (S.E.) nmols/mg protein per h) is 15% of that in brain; renal gamma-aminobutyric acid content (39.5 +/- 5.3 (S.E.) nmols/g wet wt.) is 5% of the whole brain concentration. Properties of glutamate decarboxylase were studied in homogenates of rat renal cortex and rat brain under conditions for which gamma-aminobutyric acid formation from [2,3-3H]glutamate and CO2 release from [1(-14)C]glutamate were equal. Several properties of renal glutamate decarboxylase distinguish it from the corresponding brain enzyme: (1) renal glutamate decarboxylase is selectively inhibited by cysteine sulfinic acid (Ki = 5X10(-5) M); (2) renal glutamate decarboxylase is less sensitive (Ki = 3-5X10(-5) M) to inhibition by aminooxyacetic acid than is the brain enzyme (Ki = 1X10(-6) M); (3) brain but not renal glutamate decarboxylase activity can be substantially stimulated in vitro by the addition of exogenous pyridoxal 5'-phosphate; (4) renal glutamate decarboxylase is significantly decreased in renal cortex from rats on a low-salt diet. Proximal tubules are enriched in glutamate decarboxylase compared to the activity in whole renal cortex or glomeruli (42, 22 and 14 nmols/mg protein per h, respectively). We speculate that renal gamma-aminobutyric acid synthesis does not reflect the presence of GABAergic renal nerves, but may serve a function in proximal tubular cells.

Animals↗

Turner's syndrome, 46X, del (X) (p 11), persistent complement activation and membranoproliferative glomerulonephritis.

An adolescent girl with short stature and learning disability was found to have an unusual variant of Turner's syndrome, 46X, del (X) (p 11) and an abnormal urinary sediment. Further studies demonstrated persistent depression of C3 and histologic evidence of membranoproliferative glomerulonephritis (MPGN). The occurrence of MPGN in this case may have been a manifestation of the known tendency for Turner patients to develop immunologic disease.

Biopsy, Needle↗

Antenatal betamethasone and renal ammoniagenesis in the newborn.

As part of a double-blind clinical trial of antenatal betamethasone, we studied the effects of this drug on urinary ammonia excretion in 28 premature infants. Betamethasone was administered before 34 weeks of gestation according to dosage schedules which have been shown to alter the incidence of respiratory distress syndrome. Although glucocorticoids affect renal ammoniagenesis in adults, the antenatal betamethasone trial did not augment ammonia excretion measured during the first day of postnatal life. We speculate that precocious maturation of renal ammoniagenesis cannot be triggered by glucocorticoids during the gestational period studied.

Ammonia↗